Cargando…

BRAF(V600E) mutation impinges on gut microbial markers defining novel biomarkers for serrated colorectal cancer effective therapies

BACKGROUND: Colorectal cancer (CRC) harboring BRAF(V600E) mutation exhibits low response to conventional therapy and poorest prognosis. Due to the emerging correlation between gut microbiota and CRC carcinogenesis, we investigated in serrated BRAF(V600E) cases the existence of a peculiar fecal micro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Trivieri, Nadia, Pracella, Riccardo, Cariglia, Maria Grazia, Panebianco, Concetta, Parrella, Paola, Visioli, Alberto, Giani, Fabrizio, Soriano, Amata Amy, Barile, Chiara, Canistro, Giuseppe, Latiano, Tiziana Pia, Dimitri, Lucia, Bazzocchi, Francesca, Cassano, Dario, Vescovi, Angelo L., Pazienza, Valerio, Binda, Elena
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7737386/ https://www.ncbi.nlm.nih.gov/pubmed/33317591 http://dx.doi.org/10.1186/s13046-020-01801-w

Ejemplares similares

High Levels of Prebiotic Resistant Starch in Diet Modulate a Specific Pattern of miRNAs Expression Profile Associated to a Better Overall Survival in Pancreatic Cancer
por: Trivieri, Nadia, et al.
Publicado: (2020)

Growth factor independence underpins a paroxysmal, aggressive Wnt5a(High)/EphA2(Low) phenotype in glioblastoma stem cells, conducive to experimental combinatorial therapy
por: Trivieri, Nadia, et al.
Publicado: (2022)

Different states of stemness of glioblastoma stem cells sustain glioblastoma subtypes indicating novel clinical biomarkers and high-efficacy customized therapies
por: Visioli, Alberto, et al.
Publicado: (2023)

Improving Gemcitabine Sensitivity in Pancreatic Cancer Cells by Restoring miRNA-217 Levels
por: Panebianco, Concetta, et al.
Publicado: (2021)

Stemness underpinning all steps of human colorectal cancer defines the core of effective therapeutic strategies
por: Visioli, Alberto, et al.
Publicado: (2019)

SMAD4 is Critical in Suppression of BRAF-V600E Serrated Tumorigenesis
por: Tong, Kevin, et al.
Publicado: (2021)

Microbiota Manipulation by Probiotics Administration as Emerging Tool in Cancer Prevention and Therapy
por: Panebianco, Concetta, et al.
Publicado: (2020)

A functional role of Ephrin type-B receptor 6 (EPHB6) in T-cell acute lymphoblastic leukemia
por: Colucci, Mattia, et al.
Publicado: (2023)

BRAF(V600E) cooperates with CDX2 inactivation to promote serrated colorectal tumorigenesis
por: Sakamoto, Naoya, et al.
Publicado: (2017)

BRAF(V600E)-mutated serrated colorectal neoplasia drives transcriptional activation of cholesterol metabolism
por: Rzasa, Paulina, et al.
Publicado: (2023)

Gut Microbiota Profiles Differ among Individuals Depending on Their Region of Origin: An Italian Pilot Study
por: Fontana, Andrea, et al.
Publicado: (2019)

Active BRAF-V600E is the key player in generation of a sessile serrated polyp-specific DNA methylation profile
por: Dehghanizadeh, Somaye, et al.
Publicado: (2018)

Frequent mutations of KRAS in addition to BRAF in colorectal serrated adenocarcinoma
por: Stefanius, Karoliina, et al.
Publicado: (2011)

BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma
por: Wilmott, J S, et al.
Publicado: (2013)

BRAF V600E Inhibitor (Vemurafenib) for BRAF V600E Mutated Low Grade Gliomas
por: Del Bufalo, Francesca, et al.
Publicado: (2018)

The role of BRAF V600 mutation in melanoma
por: Ascierto, Paolo A, et al.
Publicado: (2012)

MLH1–93 G/a polymorphism is associated with MLH1 promoter methylation and protein loss in dysplastic sessile serrated adenomas with BRAF(V600E) mutation
por: Fennell, Lochlan J., et al.
Publicado: (2018)

Acquired resistance to BRAF inhibition in BRAF(V600E) mutant gliomas
por: Yao, Tsun-Wen, et al.
Publicado: (2016)

Pharmacomicrobiomics: exploiting the drug-microbiota interactions in anticancer therapies
por: Panebianco, Concetta, et al.
Publicado: (2018)

High Levels of Prebiotic Resistant Starch in Diet Modulate Gene Expression and Metabolomic Profile in Pancreatic Cancer Xenograft Mice
por: Panebianco, Concetta, et al.
Publicado: (2019)

Molecular Profiling Based on KRAS/BRAF Mutation, Methylation, and Microsatellite Statuses in Serrated Lesions
por: Sugai, Tamotsu, et al.
Publicado: (2018)

Gut microbiota composition in COVID-19 hospitalized patients with mild or severe symptoms
por: Mazzarelli, Antonio, et al.
Publicado: (2022)

Immunohistochemical BRAF V600E Expression and Intratumor BRAF V600E Heterogeneity in Acral Melanoma: Implication in Melanoma-Specific Survival
por: Ito, Takamichi, et al.
Publicado: (2020)

BRAF V600K vs. BRAF V600E: a comparison of clinical and dermoscopic characteristics and response to immunotherapies and targeted therapies
por: Zengarini, Corrado, et al.
Publicado: (2022)

BRAF Inhibition in BRAF(V600)-Mutant Gliomas: Results From the VE-BASKET Study
por: Kaley, Thomas, et al.
Publicado: (2018)

Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
por: Al Hashmi, Muna, et al.
Publicado: (2020)

Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600–Mutant Tumors
por: Adashek, Jacob J., et al.
Publicado: (2022)

The CIMP Phenotype in BRAF Mutant Serrated Polyps from a Prospective Colonoscopy Patient Cohort
por: Fernando, Winnie C., et al.
Publicado: (2014)

High frequency of BRAF V600E mutations in ameloblastoma
por: Kurppa, Kari J, et al.
Publicado: (2014)

BRAF V600E-Negative Hairy Cell Leukaemia
por: Langabeer, Stephen E., et al.
Publicado: (2013)

MEK inhibitors in non-V600 BRAF mutations and fusions
por: Johnson, Douglas B., et al.
Publicado: (2020)

Targeted Therapy for Melanomas Without BRAF V600 Mutations
por: Menzer, Christian, et al.
Publicado: (2022)

Intrathoracic synovial sarcoma with BRAF V600E mutation
por: Russo, Ida, et al.
Publicado: (2023)

BRAF Non-V600 Mutations in Metastatic Colorectal Cancer
por: Liu, Junjia, et al.
Publicado: (2023)

BRAF V600E mutation and BRAF VE1 immunoexpression profiles in different types of glioblastoma
por: Tosuner, Zeynep, et al.
Publicado: (2018)

BRAF Inhibitors for BRAF V600E Mutant Colorectal Cancers: Literature Survey and Case Report
por: Peker, Yasar Subutay, et al.
Publicado: (2018)

BRAF inhibitors promote intermediate BRAF(V600E) conformations and binary interactions with activated RAS
por: Röck, Ruth, et al.
Publicado: (2019)

LGG-55. OUTCOME OF BRAF V600E PEDIATRIC GLIOMAS TREATED WITH TARGETED BRAF INHIBITION
por: Nobre, Liana, et al.
Publicado: (2020)

BRAF, MEK and EGFR inhibition as treatment strategies in BRAF V600E metastatic colorectal cancer
por: Ros, Javier, et al.
Publicado: (2021)

BRAF inhibitors in BRAF V600E-mutated ameloblastoma: systematic review of rare cases in the literature
por: Ebeling, Marcel, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_lttcj0bcrjdh8gaso2q50b7c8h